Study Reveals Significant Increase in Prescription Rejections by Insurers

A new study published in JAMA found that first-time prescription rejections by insurers increased by 67% between 2018 and 2024. Nearly half of the patients whose prescriptions were initially denied did not receive a comparable medication within 90 days. Even for those who eventually received their medication, there was an average delay of 12.2 days after the initial rejection. Rejection rates were highest in ACA marketplace plans and Medicaid managed care.

Context

The study published in JAMA highlights a troubling trend in the healthcare system, where insurers are increasingly rejecting prescriptions. Between 2018 and 2024, first-time rejections rose by 67%, indicating a shift in how insurers manage medication approvals. The findings are particularly pronounced in ACA marketplace plans and Medicaid managed care, which serve vulnerable populations.

Why it matters

The increase in prescription rejections by insurers can significantly impact patient health outcomes. Delayed access to necessary medications may worsen medical conditions and lead to higher healthcare costs. Understanding these trends is crucial for policymakers and healthcare providers aiming to improve patient care and access to medications.

Implications

The rise in prescription rejections could lead to poorer health outcomes for patients, especially those with chronic conditions. Vulnerable populations relying on ACA and Medicaid plans may face the most significant challenges. This trend may also prompt insurers to reassess their approval processes and could lead to increased scrutiny from regulators and consumer advocacy groups.

What to watch

In the near term, stakeholders may respond to these findings with calls for policy changes to address prescription rejections. Monitoring legislative proposals aimed at improving medication access will be important. Additionally, healthcare providers may need to adapt their practices to navigate the increasing complexity of prescription approvals.